Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), and Member of the Helmholtz I&I Initiative, Munich, Germany.
Front Immunol. 2020 Aug 25;11:1826. doi: 10.3389/fimmu.2020.01826. eCollection 2020.
The immune response to antigens is a key aspect of immunology, as it provides opportunities for therapeutic intervention. However, the induction of immunological tolerance is an evolving area that is still not sufficiently understood. Allergen immunotherapy (AIT) is a disease-modulating therapy available for immunoglobulin E (IgE)-mediated airway diseases such as allergic rhinitis or allergic asthma. This disease-modifying effect is not only antigen driven but also antigen specific. The specificity and also the long-lasting, often life-long symptom reduction make the therapy attractive for patients. Additionally, the chance to prevent the onset of asthma by treating allergic rhinitis with AIT is important. The mechanism and, in consequence, therapy guiding biomarker are still in its infancy. Recent studies demonstrated that the interaction of T, B, dendritic, and epithelial cells and macrophages are individually contributing to clinical tolerance and therefore underline the need for a system to monitor the progress and success of AIT. As clinical improvement is often accompanied by decreases in numbers of effector cells in the tissue, analyses of cellular responses and cytokine pattern provide a good insight into the mechanisms of AIT. The suppression of type-2 immunity is accompanied by decreased levels of type-2 mediators such as epithelial CCL-26 and interleukin (IL)-4, IL-13 produced by T cells that are constituting the immune memory and are increasingly controlled by regulatory T and B cells following AIT. Immune tolerance is also associated with increased production of type-1 mediators like interferon-gamma, tissue-homeostating factors like indoleamine 2,3-dioxygenase (IDO) expressed by macrophages and dendritic cells. Although these individual genes were convincingly demonstrated to play a role immune tolerance, they do not predict therapy outcomes of AIT on an individual level. Therefore, combinations or ratios of gene expression levels are a promising way to achieve predictive value and definition of helpful biomarker.
针对抗原的免疫反应是免疫学的一个关键方面,因为它为治疗干预提供了机会。然而,免疫耐受的诱导是一个不断发展的领域,目前还没有得到充分的理解。过敏原免疫疗法(AIT)是一种可用于治疗免疫球蛋白 E(IgE)介导的气道疾病的疾病调节疗法,例如过敏性鼻炎或过敏性哮喘。这种疾病调节作用不仅是抗原驱动的,而且是抗原特异性的。这种特异性以及长期的、常常是终身的症状缓解使该疗法对患者具有吸引力。此外,通过 AIT 治疗过敏性鼻炎来预防哮喘发作的机会也很重要。其机制以及因此作为治疗指导的生物标志物仍处于起步阶段。最近的研究表明,T、B、树突状和上皮细胞以及巨噬细胞的相互作用各自有助于临床耐受,因此需要建立一个系统来监测 AIT 的进展和成功。由于临床改善通常伴随着组织中效应细胞数量的减少,因此对细胞反应和细胞因子模式的分析为 AIT 的机制提供了很好的了解。2 型免疫的抑制伴随着 2 型介质水平的降低,例如上皮细胞 CCL-26 和 T 细胞产生的白细胞介素(IL)-4、IL-13,这些细胞构成免疫记忆,并在 AIT 后越来越受到调节性 T 和 B 细胞的控制。免疫耐受还与 1 型介质的产生增加相关,例如干扰素-γ、组织稳态因子,如巨噬细胞和树突状细胞表达的吲哚胺 2,3-双加氧酶(IDO)。尽管这些单个基因令人信服地证明在免疫耐受中发挥了作用,但它们不能预测 AIT 在个体水平上的治疗效果。因此,基因表达水平的组合或比率是实现预测价值和定义有帮助的生物标志物的有前途的方法。